Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI) Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids? Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003